共 50 条
- [5] 177Lu-PSMA-617 therapy, dosimetry and follow-up in patients with metastatic castration-resistant prostate cancer NUKLEARMEDIZIN-NUCLEAR MEDICINE, 2016, 55 (03): : 123 - 128
- [10] Response and outcome of liver metastases in patients with metastatic castration-resistant prostate cancer (mCRPC) undergoing 177Lu-PSMA-617 radioligand therapy European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48 : 103 - 112